Gain Therapeutics, Inc. (GANX)
About Gain Therapeutics, Inc.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2023
- $55.2K
- Net income
- -$20.2M
- Total assets
- $22.8M
- Market cap
- $72.5M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $18.7M
- Operating income
- -$18.7M
- Income tax
- $861.1K
- Net income
- -$20.2M
- EPS (basic)
- $-0.61
- EPS (diluted)
- $-0.61
Balance sheet
- Total assets
- $22.8M
- Current assets
- $22.2M
- Total liabilities
- $4.3M
- Current liabilities
- $3.4M
- Shareholders’ equity
- $18.6M
Cash flow
- Operating cash flow
- -$18.5M
- Investing cash flow
- -$10.5M
- Financing cash flow
- $28.4M
- Net cash flow
- -$474.0K
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $72.5M
- EPS (diluted)
- $-0.61
- Shares outstanding
- 41.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Mar 18, 2021
Gain Therapeutics, Inc. (GANX) Stock Price
- Reported a net loss of $20.2M in FY2023.
- Trading 58% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Gain Therapeutics, Inc..
Write a review
News about Gain Therapeutics, Inc.
News & sentiment via Polygon.io
Gain Therapeutics, Inc.: frequently asked questions
Is Gain Therapeutics, Inc. an American company?
Gain Therapeutics, Inc. is a US-based company headquartered in Bethesda, Maryland, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Gain Therapeutics, Inc. headquartered?
Gain Therapeutics, Inc. is headquartered in Bethesda, Maryland, United States.
Is Gain Therapeutics, Inc. publicly traded?
Yes — Gain Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol GANX on the NASDAQ.
What does Gain Therapeutics, Inc. do?
Gain Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
